Bromocriptine
Spécifications
25614-03-3Numéro CAS
247-128-5Numéro CE
(6aR,9R)-5-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamideNom IUPAC
C32H40BrN5O5Formule chimique
654.6 g/molMasse molaire
bromocriptine; 25614-03-3; Bromoergocryptine; Bromocriptin; Bromoergocriptine; Bromergocryptine; 2-Bromo-alpha-ergocryptine; Bromocriptina; 2-Bromo-alpha-ergokryptin; 2-Bromo-alpha-ergokryptine; Bromocriptinum; Ergoset; Ergocryptine, 2-bromo-; 2-Bromoergocryptine; DTXSID1022687; (+)-Bromocriptine; 3A64E3G5ZO; SANDOZ 15-754; Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'alpha)-; CHEBI:3181; DTXCID602687; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; Bromocryptin; (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman; (6aR,9R)-5-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide; 2-Bromoergokryptine; 2 Bromo alpha ergocryptine; (4R,7R)-10-bromo-N-((1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo(7.3.0.0^(2,6))dodecan-4-yl)-6-methyl-6,11-diazatetracyclo(7.6.1.0^(2,7).0^(12,16))hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide; (4R,7R)-10-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide; (6aR,9R)-5-bromo-N-((1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo(7.3.0.02,6)dodecan-4-yl)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo(4,3-fg)quinoline-9-carboxamide; 2 Bromoergocryptine; 2 Bromoergokryptine; RefChem:56423; 2 Bromo alpha ergokryptine; G02CB01; N04BC01; CB154; Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2-methylpropyl)-; (4R,7R)-10-bromo-N-((1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo(7.3.0.02,6)dodecan-4-yl)-6-methyl-6,11-diazatetracyclo(7.6.1.02,7.012,16)hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide; 247-128-5; Bromocryptine; Bromocriptinum [INN-Latin]; Bromocriptina [INN-Spanish]; CB-154; CHEMBL493; Bromocriptine (mesylate); Bromergon; Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'.alpha.)-; 2-Bromo-.alpha.-ergocryptine; CCRIS 3244; CB 154; NSC169774; EINECS 247-128-5; Bromocriptine (USAN/INN); UNII-3A64E3G5ZO; Bromokryptine; SR-01000075356; Bromocriptine [USAN:INN:BAN]; NCGC00024584-03; 08Y; 2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione; Bromocriptine+ (GTP-); Prestwick0_000121; Prestwick1_000121; Prestwick2_000121; BROMOCRIPTINE [MI]; Biomol-NT_000005; GTPL35; BROMOCRIPTINE [INN]; BROMOCRIPTINE [USAN]; Lopac0_000171; SCHEMBL25297; BROMOCRIPTINE [VANDF]; BIDD:GT0464; SPBio_002101; BROMOCRIPTINE [WHO-DD]; BPBio1_001131; SCHEMBL29364057; BDBM81993; Tox21_110907; BDBM50026707; EBC-27415; PDSP2_001500; AKOS015961273; CCG-204266; DB01200; SDCCGSBI-0050159.P003; NCGC00024584-04; NCGC00024584-05; NCGC00024584-07; NCGC00024584-09; NCGC00024584-17; NCGC00024584-28; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman; (6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide; AC-13601; AC-37665; DA-61890; NCI60_001365; CAS-25614-03-3; CS-0012283; NS00001292; C06856; D03165; EN300-19768234; Q413581; SR-01000075356-5; BRD-K14496212-001-01-1; BRD-K14496212-066-02-2; BRD-K14496212-066-04-8; (5''alpha)-2-bromo-12''-hydroxy-5''-isobutyl-2''-isopropyl-3'',6'',18-trioxoergotaman; 2-Bromo-12'-hydroxy-5'alpha-(2-methylpropyl)-3',6',18-trioxo-2'-(propan-2-yl)ergotaman; SAN 15-754; Sandoz 15-754; -Bromocryptine; -Bromoergocryptine; -Ergolactin; (4R,7R)-10-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(15),2,9,12(16),13-pentaene-4-carboxamide; (5''alpha)-2-bromo-12''-hydroxy-2''-(1-methylethyl)-5''-(2-methylpropyl)-3'',6'',18-trioxoergotaman; (5''alpha)-2-bromo-12''-hydroxy-2''-(1-methylethyl)-5''-(2-methylpropyl)ergotaman-3'',6'',18-trione; (5''alpha)-2-bromo-12''-hydroxy-5''-(2-methylpropyl)-2''-(propan-2-yl)-3'',6'',18-trioxoergotaman; (5alpha,5'beta)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-3',6',18-trioxo-2'-(propan-2-yl)ergotaman; N-[(2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxo-8,9,10,10a-tetrahydro-5H-oxazolo[[?]]pyrrolo[[?]]pyrazin-2-yl]-bromo-methyl-[?]carboxamideSynonymes
